Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT03552276 · ClinicalTrials.gov registry record · Phase 2
Long-Term Extension Trial of Tildrakizumab to Prove Its Safety in Subjects With Psoriatic Arthritis Who Have Previously Completed Study With Tildrakizumab.
A Phase 2 study, sponsored by Sun Pharmaceutical Industries Limited.
- Completed
- Registry status
- Phase 2
- Development phase
- 281
- Enrollment target
NCT03552276: Completed Phase 2 study, sponsored by Sun Pharmaceutical Industries Limited.
NCT03552276 is a Phase 2 study that has completed, run by Sun Pharmaceutical Industries Limited. The registered enrollment target is 281 participants, above the 133-participant average among 30,622 other Phase 2 trials with a reported enrollment target (111% higher). According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT03552276, a Phase 2 study, has completed, sponsored by Sun Pharmaceutical Industries Limited.
- COMPLETED
- Registry status
- Phase 2
- Development phase
- 281 participants
- Enrollment target
Study Summary
A long term study to demonstrate the safety of Tildrakizumab in Subjects with Psoriatic Arthritis who Have Previously Completed Study with Tildrakizumab
Primary Outcome
Please refer to Adverse event section for more information
Interventions
- DRUG SUNPG18_07 I (Tildrakizumab 200 mg)
- DRUG SUNPG18_07 II (Tildrakizumab 100 mg)
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 281 participants |
| Start Date | 2018-07-11 |
| Est. Completion | 2023-09-18 |
| Phase | Phase 2 |
What the finished NCT03552276 record still lists
NCT03552276 is an interventional study that assigns participants to a tested intervention. The registered 281 participants enrollment target is mid-sized for trials with a published cap, above the 133-participant average among 30,622 other Phase 2 trials with a reported enrollment target (111% higher).
The record links to 0 conditions, and to 2 interventions - of which SUNPG18_07 I (Tildrakizumab 200 mg) is the first listed.
NCT03552276 does not publish any study locations in the registry export this page uses.
Frequently Asked Questions
What is clinical trial NCT03552276 about?
NCT03552276 is a clinical study titled "Long-Term Extension Trial of Tildrakizumab to Prove Its Safety in Subjects With Psoriatic Arthritis Who Have Previously Completed Study With Tildrakizumab.". A long term study to demonstrate the safety of Tildrakizumab in Subjects with Psoriatic Arthritis who Have Previously Completed Study with Tildrakizumab
What is the current status of trial NCT03552276?
This trial is currently completed. It is a Phase 2 study. The enrollment target is 281 participants. The study started on 2018-07-11. Estimated completion is 2023-09-18.
What interventions are being tested in trial NCT03552276?
The interventions under investigation include: SUNPG18_07 I (Tildrakizumab 200 mg) (DRUG), SUNPG18_07 II (Tildrakizumab 100 mg) (DRUG).
Who is sponsoring clinical trial NCT03552276?
This trial is sponsored by Sun Pharmaceutical Industries Limited, which has 38 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
How this trial's enrollment target compares
Where NCT03552276's enrollment target sits among peer trials
281 196th of 2000 higher than 1,805 of 2,000 other Phase 2 trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Phase 2 trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT04521231 · 281 participants · Phase 1
A Study of Subcutaneous Blinatumomab Administration in Participants With R/R and MRD+ B-ALL
- NCT06190730 · 281 participants · NA
REmote Symptom COllection to improVE postopeRative Care
- NCT02860364 · 282 participants · NA
Comparing Hypothermic Temperatures During Hemiarch Surgery
- NCT04867395 · 282 participants · NA
A Multi-Phase Study Examining Hospital to Home Transitions for Children With Medical Complexity
Similar registry start date
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia
- NCT07125183 · started 2026-12 · Phase 2
Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma
- NCT07292298 · started 2026-11 · Phase 2
Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates
- NCT04263285 · started 2026-10 · NA
Treatment of Depression Post-SCI